Abstract
Chronic lymphocytic leukemia (CLL) is the most prevalent leukemia in the Western hemisphere. The recent availability of novel targeted therapies, namely Bruton's tyrosine kinase, phosphoinositide-3 kinase, and BCL-2 inhibitors, have revolutionized the treatment algorithm for CLL but have not yet resulted in cure. Advances in the field of immuno-oncology and T cell engineering brought chimeric antigen receptor (CAR) T cell therapy from the laboratory to the clinic for treatment of B cell lymphoid malignancies and has improved the disease response and survival outcomes of various types of relapsed and/or refractory B cell lymphomas. While acknowledging that there are no approved CAR T cell therapies for CLL at this time, in this comprehensive review we explore novel targets for CAR T cell therapy in CLL and highlight the promising results of CAR T cell trials reported to date. Furthermore, we shed light on future areas of development, including multitarget CAR T cell products for this disease.
Original language | English (US) |
---|---|
Pages (from-to) | 5-17 |
Number of pages | 13 |
Journal | Transplantation and Cellular Therapy |
Volume | 28 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2022 |
Keywords
- Chimeric antigen receptor T cell therapy
- Chronic lymphocytic leukemia
- Novel antigen target
- Response rate
- Survival
ASJC Scopus subject areas
- Hematology
- Transplantation
- Immunology and Allergy
- Cell Biology
- Molecular Medicine
- General Medicine